PREMENSTRUAL SYNDROME (PMS) – A REVIEW OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT APPROACHES
Abstract
Premenstrual Syndrome (PMS) and its severe form, Premenstrual Dysphoric Disorder (PMDD), are prevalent cyclical disorders affecting the emotional, behavioral, and physical well-being of women of reproductive age. This review aims to present an overview of the current understanding of PMS/PMDD and critically examine both pharmacological and non-pharmacological treatment methods. Based on recent clinical trials and systematic reviews, selective serotonin reuptake inhibitors (SSRIs), hormonal therapies, and emerging drugs like sepranolone and ulipristal acetate demonstrate efficacy in symptom reduction (Bäckström et al., 2021; Comasco et al., 2020; Maranho et al., 2023). Simultaneously, cognitive-behavioral therapy (CBT), mindfulness-based interventions, nutritional supplements, herbal medicine, and even open-label placebos are gaining attention as effective non-pharmacological alternatives (Frey Nascimento et al., 2025; Reilly et al., 2023; Shojiasi et al., 2024; Sultana et al., 2022). Despite promising findings, further high-quality research is needed to tailor personalized and integrative treatment strategies.
References
Aoki, M., Suzuki, M., Suzuki, S., et al. (2024, May 10). Characterization of mood and emotion regulation in PMS/PMDD using NIRS. arXiv. https://doi.org/10.48550/arXiv.2405.06457
Bäckström, T., Ekberg, K., Hirschberg, A. L., et al. (2021). Efficacy and safety of sepranolone in PMDD: Randomized double-blind study. Psychoneuroendocrinology, 133, 105426. https://doi.org/10.1016/j.psyneuen.2021.105426
Brown, D., Smith, D., Osborn, E., & Wittkowski, A. (2024). Experiences and psychological impact of living with premenstrual disorders: A systematic review. Frontiers in Psychiatry, 15, 1440690. https://doi.org/10.3389/fpsyt.2024.1440690
Cunningham, J., Yonkers, K. A., O’Brien, S., & Eriksson, E. (2021). Premenstrual syndrome: A common but underrated entity. Journal of the Turkish-German Gynecological Association, 22(3), 202–211. https://doi.org/10.4274/jtgga.galenos.2021.2020.0133
Hantsoo, L., & Epperson, C. N. (2020). Allopregnanolone in PMDD: Evidence for dysregulated sensitivity to GABA-A receptor–modulating neuroactive steroids. Neurobiology of Stress, 12, 100213. https://doi.org/10.1016/j.ynstr.2020.100213
Hantsoo, L., & Riddle, J. (2021). Treatment of premenstrual dysphoric disorder (PMDD): Advances and challenges. Advances in Psychiatry and Behavioral Health, 1(1), 91–106. https://doi.org/10.1016/j.ypsc.2021.05.009
Jespersen, C., Lauritsen, M. P., Frokjaer, V. G., & Schroll, J. B. (2024). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews, 8, CD001396. https://doi.org/10.1002/14651858.CD001396.pub4
Maranho, M., Guapo, V. G., de Rezende, M. G., et al. (2023). Low doses of fluoxetine for emotional premenstrual syndrome: Pilot randomized controlled trial. Psychoneuroendocrinology, 157, 106360. https://doi.org/10.1016/j.psyneuen.2023.106360
Marais-Thomas, H., Chapelle, F., de Vaux-Boitouzet, V., & Bouvet, C. (2024). PMDD: Drug and psychotherapeutic management – A literature review. L’Encéphale, 50(2), 211–232. https://doi.org/10.1016/j.encep.2023.08.007
Meth, E. M. S., Nôga, D. A., Dubol, M., et al. (2025). The impact of pharmacotherapy for PMDD on sleep. Sleep Medicine Reviews, 80, 102069. https://doi.org/10.1016/j.smrv.2025.102069
Modzelewski, S., Oracz, A., Żukow, X., Iłendo, K., Śledzikowka, Z., & Waszkiewicz, N. (2024). Premenstrual syndrome: New insights into etiology and review of treatment methods. Frontiers in Psychiatry, 15, 1363875. https://doi.org/10.3389/fpsyt.2024.1363875
Nexha, A., Caropreso, L., de Azevedo Cardoso, T., et al. (2024). Biological rhythms in premenstrual syndrome and PMDD: A systematic review. BMC Women’s Health, 24(1), 551. https://doi.org/10.1186/s12905-024-03395-3
Pearlstein, T., & Steiner, M. (2023). Management of premenstrual dysphoric disorder: A scoping review. Frontiers in Psychiatry, 14, 9790166. https://doi.org/10.3389/fpsyt.2023.9790166
Reilly, T. J., Lindner, P., Berg, M., Parling, T., Taylor, D., & Andersson, G. (2023). Emotion regulation-based internet-delivered cognitive behavioural therapy for premenstrual dysphoric disorder: Study protocol for a randomised controlled trial in Sweden. BMJ Open, 13(1), e069649. https://doi.org/10.1136/bmjopen-2024-091649
Shojiasi, N., Mohamadi, F., et al. (2024). Emotion-focused therapy for PMDD: Randomized controlled trial. BMC Psychiatry, 24, 568. https://doi.org/10.1186/s12888-024-05681-8
Sultana, A., Heyat, M. B. B., Rahman, K., et al. (2022). A systematic review and meta-analysis of premenstrual syndrome with special emphasis on herbal medicine and nutritional supplements. Pharmaceuticals, 15(11), 1371. https://doi.org/10.3390/ph15111371
Frey Nascimento, A., Gaab, J., Degen, B., Locher, C., Kossowsky, J., Meyer, A., et al. (2025, March 25). Efficacy of open-label placebos for premenstrual syndrome: A randomised controlled trial. BMJ Evidence-Based Medicine. https://ebm.bmj.com/content/early/2025/03/05/bmjebm-2024-112875
Comasco, E., Kopp Kallner, H., Bixo, M., Hirschberg, A. L., Nyback, S., de Grauw, H., Epperson, C. N., & Sundström-Poromaa, I. (2020). Ulipristal acetate for treatment of premenstrual dysphoric disorder: A proof-of-concept randomized controlled trial. American Journal of Psychiatry, 177(12), 1125–1133. https://pubmed.ncbi.nlm.nih.gov/33297719/
Nurdilan Şener Çetin, N., & Şolt Kırca, A. (2023). The effect of a mindfulness-based stress reduction program on premenstrual symptoms: A randomized controlled trial. Journal of Midwifery & Women’s Health, 68(5), 604–610. https://pubmed.ncbi.nlm.nih.gov/37335817/
Endo, Y., Chikumi, J., Sato, E., Ikebuchi, A., Sunada, H., Noma, H., et al. (2024). Exploratory study to evaluate the efficacy and safety of the Kampo medicine, kamishoyosan, for premenstrual syndrome: Study protocol for an open-label, randomized controlled trial. Medicine (Baltimore), 5(1), e00307. https://journals.lww.com/md-cases/fulltext/2024/01000/exploratory_study_to_evaluate_the_efficacy_and.2.aspx
Views:
14
Downloads:
4
Copyright (c) 2025 Aleksandra Białas, Weronika Lusarczyk, Natalia Sapeda, Aleksandra Młocek, Adrianna Truszyńska-Zawisza, Zuzanna Romanowska, Karolina Gorczyca, Kamil Kerknawi, Paulina Mikulec, Emilia Loch
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
